Brandt J E, Galy A H, Luens K M, Travis M, Young J, Tong J, Chen S, Davis T A, Lee K P, Chen B P, Tushinski R, Hoffman R
Hematology/Oncology Section, University of Illinois at Chicago, USA.
Exp Hematol. 1998 Sep;26(10):950-61.
In vitro exposure of murine hematopoietic stem cells (HSCs) to cell cycle-inducing cytokines has been shown to result in a defect in the ability of these cells to engraft. We used a porcine microvascular endothelial cell (PMVEC) line in conjunction with exogenous interleukin (IL)-3, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), and stem cell factor (SCF) to expand human HSCs that express the CD34 and Thy-1 antigens but lack lineage-associated markers (CD34+Thy-1+Lin- cells). Ex vivo expansion of hematopoietic cells was evaluated in comparison to stromal cell-free, cytokine-supplemented cultures. Cells expressing the CD34+Thy-1+Lin- phenotype were detectable in both culture systems for up to 3 weeks. These cells were reisolated from the cultures and their ability to engraft human fetal bones implanted into SCID mice (SCID-hu bone) was tested. HSCs expanded in PMVEC coculture were consistently capable of competitive marrow repopulation with multilineage (CD19+ B lymphoid, CD33+ myeloid, and CD34+ cells) progeny present 8 weeks postengraftment. In contrast, grafts composed of cells expanded in stroma-free cultures did not lead to multilineage SCID-hu bone repopulation. Proliferation analysis revealed that by 1 week of culture more than 80% of the cells in the PMVEC cocultures expressing the primitive CD34+CD38- phenotype had undergone cell division. Fewer than 1% of the cells that proliferated in the absence of stromal cells remained CD34+CD38-. These data suggest that the proliferation of HSCs in the presence of IL-3, IL-6, GM-CSF, and SCF without stromal cell support may result in impairment of engraftment capacity, which may be overcome by coculture with PMVECs.
已表明,鼠类造血干细胞(HSC)在体外暴露于诱导细胞周期的细胞因子会导致这些细胞的植入能力出现缺陷。我们使用猪微血管内皮细胞(PMVEC)系,结合外源性白细胞介素(IL)-3、IL-6、粒细胞-巨噬细胞集落刺激因子(GM-CSF)和干细胞因子(SCF)来扩增表达CD34和Thy-1抗原但缺乏谱系相关标志物(CD34+Thy-1+Lin-细胞)的人HSC。与无基质细胞、补充细胞因子的培养物相比,对造血细胞的体外扩增进行了评估。在两种培养系统中均可检测到表达CD34+Thy-1+Lin-表型的细胞长达3周。从培养物中重新分离出这些细胞,并测试它们植入植入SCID小鼠(SCID-hu骨)的人胎骨的能力。在PMVEC共培养中扩增的HSC始终能够竞争性地重建造血,移植后8周出现多谱系(CD19+B淋巴细胞、CD33+髓细胞和CD34+细胞)后代。相比之下,由在无基质培养物中扩增的细胞组成的移植物并未导致多谱系SCID-hu骨重建造血。增殖分析显示,培养1周时,PMVEC共培养物中超过80%表达原始CD34+CD38-表型的细胞发生了细胞分裂。在无基质细胞的情况下增殖细胞中,不到1%的细胞仍为CD34+CD38-。这些数据表明,在没有基质细胞支持的情况下,IL-3、IL-6、GM-CSF和SCF存在时HSC的增殖可能导致植入能力受损,而与PMVEC共培养可能克服这一问题。